No material catalyst — the filing is a standard clinical-stage pipeline update. Monitor for future data readouts from the ongoing Phase 2 trial (NCT03878849) and the separate Phase 2 SCLC combination trial for potential catalysts. No immediate trading action warranted.
Price Chart
Executive Summary
Allarity Therapeutics filed an 8-K announcing a Trial-in-Progress poster presentation for its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026. The poster describes the study design and clinical rationale for stenoparib in platinum-resistant ovarian cancer but contains no new clinical data. This is a routine scientific conference update with no material financial or operational impact.
Key Facts
- Allarity presented a Trial-in-Progress poster (166TiP) at ESMO Gynaecological Cancers Congress 2026, held June 17-19 in Copenhagen.
- The poster covers the Phase 2 trial of stenoparib (2X-121) in advanced platinum-resistant or platinum-ineligible ovarian cancer.
- As a Trial-in-Progress presentation, the poster includes study design and rationale only — no new clinical data were disclosed.
- Principal Investigator Kathleen N. Moore, M.D., presented the poster.
- The company is a Phase 2 clinical-stage biopharmaceutical with a $22M market cap.
Financial Impact
No financial figures disclosed. Routine conference presentation with no revenue, cost, or capital impact.
Risk Factors
- No new efficacy or safety data were released; the trial remains early-stage with binary readout risk.
- The company is pre-revenue with a $22M market cap, dependent on successful clinical development and financing.
- Prior clinical observations may not be confirmed as the trial matures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-070382 |
| Document: ea0295409-8k_allarity.htm | 0001213900-26-070382 |
| Document: 0001213900-26-070382-index-headers.html | 0001213900-26-070382 |
| Document: 0001213900-26-070382-index.html | 0001213900-26-070382 |
| Document: 0001213900-26-070382.txt | 0001213900-26-070382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9200 (−11.54%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 $0.9200 | ▼ −4.67% | ▼ −5.39% | $0.9200 (−4.67%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9200 (−5.00%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9200 (−20.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9200 (−21.37%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9200 (−24.59%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9200 (−32.85%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9200 (−30.83%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9200 (−32.35%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9200 (−35.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers